Asialoglycoprotein receptor-mediated gene transfer using novel galactosylated cationic liposomes.

We synthesized three novel galactosylated cholesterol derivatives, cholesten-5-yloxy-N-(4-((1-imino-c-beta-D-thiogalactosyl+ ++-ethyl)amino) butyl)formamide (Gal-C4-Chol) and its ethyl formamide and hexyl formamide analogues (Gal-C2-Chol, Gal-C6-Chol), to prepare liposomal gene carriers possessing the cationic charge necessary for plasmid DNA binding and galactose residues as a targetable ligand for liver parenchymal cells. Liposome/DNA complexes prepared with these lipids showed low cytotoxicity in human hepatoma HepG2 cells. Gal-C4-Chol/DC-Chol/DOPE(3:3:4) liposomes, consisting of 3:3:4 mixtures of Gal-C4-Chol, 3beta[N',N', N'-dimethylaminoethane)-carbamoyl] cholesterol (DC-Chol), and dioleoylphosphatidylethanolamine (DOPE), showed higher transfection activity and [32P]DNA uptake than DC-Chol/DOPE(6:4) liposomes. The presence of 20 mM galactose significantly inhibited both transfection efficiency and uptake of DNA of Gal-C4-Chol/DC-Chol/DOPE(3:3:4) and Gal-C4-Chol/DOPE(6:4) liposomes, but not those of DC-Chol/DOPE(6:4) liposomes. These results indicate that the liposome/DNA complexes prepared using novel galactosylated cholesterol derivatives are efficiently recognized by asialoglycoprotein receptors and internalized and lead to gene expression. In addition, we found that the galactosylated cholesterol derivative with a longer spacer showed higher transfection activity.

[1]  H. Yamada,et al.  Syntheses of novel galactosyl ligands for liposomes and the influence of the spacer on accumulation in the rat liver. , 1995, Biological & pharmaceutical bulletin.

[2]  C H Wu,et al.  Receptor-mediated in vitro gene transformation by a soluble DNA carrier system. , 1987, The Journal of biological chemistry.

[3]  John W. Park,et al.  Sterically stabilized anti-HER2 immunoliposomes: design and targeting to human breast cancer cells in vitro. , 1997, Biochemistry.

[4]  R. Smith,et al.  Lowry determination of protein in the presence of Triton X-100. , 1975, Analytical biochemistry.

[5]  James M. Wilson,et al.  Successful ex vivo gene therapy directed to liver in a patient with familial hypercholesterolaemia , 1994, Nature Genetics.

[6]  Leaf Huang,et al.  Overcoming the inhibitory effect of serum on lipofection by increasing the charge ratio of cationic liposome to DNA , 1997, Gene Therapy.

[7]  R. Kumar,et al.  Enhanced gene delivery and mechanism studies with a novel series of cationic lipid formulations. , 1994, The Journal of biological chemistry.

[8]  M. Hashida,et al.  Targeted delivery of human recombinant superoxide dismutase by chemical modification with mono- and polysaccharide derivatives. , 1992, The Journal of pharmacology and experimental therapeutics.

[9]  C. Wu,et al.  Receptor-mediated gene delivery and expression in vivo. , 1988, The Journal of biological chemistry.

[10]  K. Koike,et al.  Receptor-mediated transfer of pSV2CAT DNA to mouse liver cells using asialofetuin-labeled liposomes. , 1995, Gene therapy.

[11]  L. Huang,et al.  A novel cationic liposome reagent for efficient transfection of mammalian cells. , 1991, Biochemical and biophysical research communications.

[12]  K. Koike,et al.  Receptor-mediated transfer of pSV2CAT DNA to a human hepatoblastoma cell line HepG2 using asialofetuin-labeled cationic liposomes. , 1995, Gene.

[13]  Leaf Huang,et al.  Time-dependent maturation of cationic liposome–DNA complex for serum resistance , 1998, Gene Therapy.